Sanofi Moves into MicroRNA, Signs Preclinical Platform Deal with Regulus

With $25 million upfront, $10 million in equity and hundreds of millions of dollars in possible milestones, Sanofi makes a significant early bet on the latest RNA-based therapeutic class to emerge.